Antimicrobial resistance empirical and statistical evidence-base: a report from the Department of Health Antimicrobial Resistance Strategy Analytical Working Group

Document type
Corporate author(s)
Great Britain. Department of Health.
Department of Health
Date of publication
1 December 2014
Health Services
Social welfare
Material type

Download (616KB )

They are primarily used to treat infectious diseases in humans and animals, but are also of great value in the prevention of infections when used as prophylaxis, such as in the prevention of infections at the site of a surgical incision or prevention of neutropenic sepsis in patients undergoing chemotherapy treatment for cancer. Antibiotic use has increased to such an extent that resistance to them has emerged and spread in many organisms. Infections with resistant organisms now occur both in community and hospital populations. However AMR infections in healthcare settings are to which most deaths are related, an estimated 25 000 patients die annually in the EU from an infection with multidrug-resistant (MDR) bacteria. AMR has reached the stage of threatening some medical procedures, by making them too risky to perform.

This report provides a broad overview of the current situation of antimicrobial resistance (AMR) in bacteria. Its primary aim is to bring together the evidence upon which scenario-based analytical work can be undertaken to assess the impact of emerging AMR in specific pathogens, groups of pathogens, or in particular types of infection or patient groups. The literature on many aspects of AMR is vast and impossible to encapsulate in its entirety in such a report.